Apixaban
For Laboratory Research Only. Not for Clinical or Personal Use.
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Apixaban
Description :
Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively[1]. Apixaban is in development for the prevention and treatment of various thromboembolic diseases[2].CAS Number :
[503612-47-3]Product Name Alternative :
BMS-562247-01UNSPSC :
12352005Hazard Statement :
H302, H315, H320, H335Target :
Factor XaType :
Reference compoundRelated Pathways :
Metabolic Enzyme/ProteaseApplications :
COVID-19-immunoregulationField of Research :
Cardiovascular Disease; CancerAssay Protocol :
https://www.medchemexpress.com/Apixaban.htmlPurity :
99.99Solubility :
DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mLSmiles :
NC(C1=NN(C2=C1CCN(C2=O)C3=CC=C(C=C3)N4CCCCC4=O)C5=CC=C(C=C5)OC)=OMolecular Formula :
C25H25N5O4Molecular Weight :
459.50Precautions :
H302, H315, H320, H335References & Citations :
[1]Pinto DJ, et al. Discovery of 1- (4-methoxyphenyl) -7-oxo-6- (4- (2-oxopiperidin-1-yl) phenyl) -4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2007 Nov 1;50 (22) :5339-56.|[2]Wong PC, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008 May;6 (5) :820-9|[3]Zhang D, et al. Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. J Thromb Thrombolysis. 2010 Jan;29 (1) :70-80|[4]He K, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011 Sep;36 (3) :129-39Shipping Conditions :
Blue IceStorage Conditions :
-20°C (Powder, protect from light)Scientific Category :
Reference compound1Clinical Information :
Launched

